Table 2 Top 25 pathways with FDR corrected P < 0.01 from Metacore GeneGO pathway analysis. Remaining pathways with corrected P < 0.01 summarized in Additional file 8: Table S5. *Ratio: Number of genes in input list found in the pathway/Total number of genes in the pathway
Pathway | Corrected P | *Ratio | Encoded proteins/protein complexes in input list |
|---|---|---|---|
Aberrant B-Raf signaling in melanoma progression | 7.456E-07 | 10/55 | BAD, NOTCH1 (NICD), AKT1, Nicastrin, CBP, mTOR, ERK1/2, ERK2 (MAPK1), Mcl-1, AKT(PKB) |
Signal transduction_PTMs in BAFF-induced signaling | 3.454E-06 | 9/51 | BAD, ERK1 (MAPK3), AKT1, MEKK1(MAP3K1), FKHR, mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
Immune response_IL-15 signaling | 9.177E-06 | 9/61 | ERK1 (MAPK3), AKT1, MEKK1(MAP3K1), mTOR, ERK1/2, UFO, ERK2 (MAPK1), Mcl-1, AKT(PKB) |
Development_Ligand-independent activation of ESR1 and ESR2 | 9.177E-06 | 8/44 | EGFR, ERK1 (MAPK3), PKA-cat (cAMP-dependent), G-protein alpha-s, CBP, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
Translation_Regulation of EIF4F activity | 3.883E-05 | 8/54 | EGFR, MEKK1(MAP3K1), eIF4B, PP2A catalytic, eIF4A, mTOR, ERK1/2, AKT(PKB) |
Aberrant production of IL-2 and IL-17 in SLE T cells | 5.718E-05 | 8/58 | PP2A cat (alpha), NOTCH1 (NICD), PKA-cat (cAMP-dependent), CBP, mTOR, ERK1/2, AKT(PKB), NOTCH1 precursor |
IGF family signaling in colorectal cancer | 6.001E-05 | 8/60 | ERK1 (MAPK3), IBP, MNK2(GPRK7), mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB), Clusterin |
Apoptosis and survival_BAD phosphorylation | 6.001E-05 | 7/42 | BAD, EGFR, PKA-cat (cAMP-dependent), PP2A catalytic, G-protein alpha-s, ERK1/2, AKT(PKB) |
Influence of smoking on activation of EGFR signaling in lung cancer cells | 7.422E-05 | 7/44 | EGFR, ERK1 (MAPK3), PKA-cat (cAMP-dependent), MEKK1(MAP3K1), G-protein alpha-s, ERK1/2, ERK2 (MAPK1) |
Immune response_IL-6 signaling pathway via JAK/STAT | 1.810E-04 | 8/72 | MEKK1(MAP3K1), FKHR, CCL2, CBP, mTOR, Mcl-1, AKT(PKB), gp130 |
Signal transduction_Erk Interactions: Inhibition of Erk | 1.810E-04 | 6/34 | MKP-3, PKA-cat (cAMP-dependent), PP2A catalytic, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
Oxidative stress_ROS-mediated activation of MAPK via inhibition of phosphatases | 1.810E-04 | 6/34 | EGFR, MKP-3, SOD2, PP2A catalytic, ERK1/2, SOD1 |
Apoptosis and survival_NGF/ TrkA PI3K-mediated signaling | 2.255E-04 | 8/77 | BAD, N-WASP, AKT1, FKHR, ILK, mTOR, ERK1/2, AKT(PKB) |
PGE2 pathways in cancer | 2.255E-04 | 7/55 | EGFR, ERK1 (MAPK3), TGF-alpha, PKA-cat (cAMP-dependent), G-protein alpha-s, ERK2 (MAPK1), AKT(PKB) |
Immune response_Oncostatin M signaling via MAPK | 2.275E-04 | 6/37 | ERK1 (MAPK3), MEKK1(MAP3K1), CCL2, ERK1/2, ERK2 (MAPK1), gp130 |
Development_Beta-adrenergic receptors transactivation of EGFR | 2.275E-04 | 6/37 | EGFR, ERK1 (MAPK3), PP2A catalytic, mTOR, ERK1/2, ERK2 (MAPK1) |
Development_Regulation of lung epithelial progenitor cell differentiation | 3.976E-04 | 6/41 | FOXP2, SMAD4, Frizzled, NOTCH1 receptor, FOXP1, O-fucose |
Regulation of Tissue factor signaling in cancer | 4.726E-04 | 6/43 | EGFR, ERK1 (MAPK3), mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
Development_Adenosine A2A receptor signaling | 4.726E-04 | 6/43 | BAD, PKA-cat (cAMP-dependent), MEKK1(MAP3K1), G-protein alpha-s, ERK1/2, AKT(PKB) |
Development_VEGF signaling via VEGFR2 - generic cascades | 5.478E-04 | 8/93 | ERK1 (MAPK3), MEKK1(MAP3K1), CCL2, Vinculin, ERK1/2, ERK2 (MAPK1), AKT(PKB), Fyn |
Signal transduction_mTORC2 downstream signaling | 5.478E-04 | 7/68 | BAD, AKT1, PKA-cat (cAMP-dependent), FKHR, mTOR, Mcl-1, AKT(PKB) |
Transcription_Hypoxia- and receptor-mediated HIF-1 activation | 5.478E-04 | 6/46 | EGFR, FKHR, MNK2(GPRK7), CBP, ERK1/2, AKT(PKB) |
Transcription_Androgen Receptor nuclear signaling | 5.478E-04 | 6/46 | EGFR, AKT1, PKA-cat (cAMP-dependent), Frizzled, ERK2 (MAPK1), AKT(PKB) |
Signal transduction_PTEN pathway | 5.478E-04 | 6/46 | BAD, EGFR, ILK, mTOR, ERK1/2, AKT(PKB) |
Immune response_IL-4 signaling pathway | 5.478E-04 | 8/94 | BAD, PDE3A, MEKK1(MAP3K1), FKHR, mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB) |